Baseline characteristics may impact treatment duration of cabazitaxel in patients with mCRPC: a subanalysis of data from a post-marketing surveillance.
Nobuaki MatsubaraHideyasu MatsuyamaHirotaka KazamaTakeshi SetoYoshinori SunagaKazuhiro SuzukiPublished in: Japanese journal of clinical oncology (2023)
Post-marketing surveillance data suggest physicians should individualize cabazitaxel treatment based on certain patient characteristics at baseline.